DLL4 and neoplasm: We validated the topological descriptors on data from studies in which tumors were treated with different agents with known effects on tumor vasculature: vascular targeting agents DC101 and anti-Dll4 in the intravital data and bevacizumab in the ultramicroscopy data (see Fig. 4).